Results 161 to 170 of about 143,561 (278)

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

MedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang   +9 more
wiley   +1 more source

Epidemiological and Histopathological Characterization of Endometrial Carcinoma: A Retrospective Cohort from Romania. [PDF]

Diagnostics (Basel)
Muraru A, Stepan AE, Margaritescu C, Florescu MM, Badiu AM, Cretu IO, Andreiana BC, Ciurea RN.   +7 more
europepmc   +1 more source

Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next? [PDF]

, 2019
Cripe, James C, Fuh, Katherine C, Litz, Taylor, Lopez, Heather, Mills, Kathryn A, Mutch, David G, Powell, Matthew A, Sun, Lulu, Thaker, Premal H   +8 more
core   +1 more source

Immunoreactivity for CD34, Desmin, Keratins, KIT, Alpha‐Smooth Muscle Actin, S100, and Vimentin in Malignant Mesenchymal Neoplasms in Guinea Pigs: A Series of 62 Cases From a Single Institution

Veterinary Medicine and Science, Volume 12, Issue 2, March 2026.
Immunohistochemical expression of CD34, desmin, keratin AE1/AE3, keratin 8/18, KIT, SMA, S100, and vimentin in normal guinea pig skin serving as both positive and negative external tissue control. All images immunohistochemical staining, 200× magnification, scale bar 100 µm. (A) CD34 stained only vascular endothelium (arrow).
Jiří Lenz, Miša Škorič, František Tichý, Luděk Fiala   +3 more
wiley   +1 more source

PTBP1 functions as a suppressor of ferroptosis in endometrial carcinoma cells by stabilizing SLC7A11 mRNA. [PDF]

Discov Oncol
Zhu K, Zhang K, Li H, Shen Y, Wang L, Hu Q, Xing H, Han L.   +7 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1250-1270, March 2026.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Implementation of Robotic-Assisted Surgery for the Treatment of Patients with Endometrial Carcinoma. [PDF]

Cancers (Basel)
Shaalan W, Haßdenteufel K, Hoppe F, Sinn P, Togawa R, Tretschock LM, Batarseh D, Ylitalo H, Hassan N, Schäfgen B, Hennigs A, Smetanay K, Schneeweiss A, Nees LK, Riedel F, Zivanovic O.   +15 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Solitary mandibular recurrence of uterine endometrial carcinoma successfully treated with chemotherapy alone: A case report. [PDF]

Gynecol Oncol Rep
Ishida T, Maenohara S, Yagi H, Yahata H, Kato K.   +4 more
europepmc   +1 more source

Predictive Biomarkers for Immunotherapy in Endometrial Carcinoma. [PDF]

Cancers (Basel)
Pizzimenti C, Fiorentino V, Pepe L, Franchina M, Ruggeri C, Ercoli A, Ciappina G, Berretta M, Tuccari G, Ieni A.   +9 more
europepmc   +1 more source